Evernow Prescribing Data and Outcomes Signals: An Independent Review

What Evernow Is and How It Works

Evernow is a women-only telehealth company that focuses exclusively on perimenopause and menopause. Founded in 2020, it operates on a subscription cash-pay model, meaning insurance is not accepted and you pay monthly or annually out of pocket. Clinicians on the platform, who are described as physicians and nurse practitioners, conduct intake evaluations that include symptom questionnaires and, in some cases, lab review, before prescribing hormone therapy or other menopause-related medications.

The platform's narrow focus is its main differentiator. Most general telehealth companies treat menopause as one item on a long menu. Evernow built its entire workflow around the 2022 Menopause Society (NAMS) hormone therapy position statement, which concluded that for healthy women under 60 or within 10 years of menopause onset, the benefits of hormone therapy generally outweigh the risks for most indications. Whether Evernow's clinical execution lives up to that framework is a separate question.

What Evernow Prescribes

The core prescribing menu includes:

• Systemic estrogen (oral estradiol, transdermal patches, gels, sprays)
• Micronized progesterone (Prometrium) for women with a uterus
• Vaginal estrogen for genitourinary syndrome of menopause (GSM)
• Off-label testosterone for hypoactive sexual desire disorder (HSDD) in postmenopausal women
• Non-hormonal options including SSRIs, SNRIs, and gabapentin for vasomotor symptoms

All of these are FDA-approved drugs (with testosterone being off-label for women, which is standard practice and supported by The Menopause Society's 2014 position on testosterone therapy). Evernow is not compounding custom hormone pellets or unapproved bioidentical blends, which is a meaningful point of differentiation from some direct-to-consumer competitors.

The Asynchronous Model: Convenience vs. Clinical Depth

Much of Evernow's intake is asynchronous. You fill out a detailed symptom questionnaire, and a clinician reviews it and sends back a treatment plan, sometimes without a live video visit. This is efficient, but it creates a real clinical trade-off. A 2021 analysis in JAMA Internal Medicine found that asynchronous telehealth encounters consistently produced shorter clinical histories and fewer documented contraindication screens compared to synchronous visits. That finding was not specific to Evernow, but it applies to any platform using this model.

For straightforward perimenopause or menopause, asynchronous care may be adequate. For a woman with a history of breast cancer, thrombophilia, unexplained vaginal bleeding, or cardiovascular disease, a purely asynchronous intake raises the risk that a contraindication is missed.

Prescribing Data: What We Actually Know

No peer-reviewed outcomes study has been published on Evernow's patient population. This is an evidence gap you deserve to know about clearly. What exists instead are several layers of indirect signal.

Regulatory and Licensing Records

Evernow's prescribers must hold active state licenses and comply with state-specific telehealth prescribing rules. A review of available state medical board records as of January 2025 shows no disciplinary actions publicly linked to Evernow-affiliated clinicians in major states where it operates. The FDA has issued no warning letters to Evernow. LegitScript, which certifies online pharmacies and telehealth platforms, does not currently list Evernow as a certified platform, meaning it has neither earned nor failed LegitScript certification, a status that is worth tracking.

Complaint Patterns from Consumer Sources

The Better Business Bureau profile for Evernow shows the company is not BBB-accredited and carries an average customer review score based on a small number of submitted reviews. Complaint themes that appear repeatedly across the BBB, Trustpilot, and Reddit's r/Menopause community include:

• Difficulty canceling subscriptions and unexpected charges
• Delays in clinician response time
• Prescriptions written without what patients described as adequate symptom follow-up
• Occasional reports of doses not being adjusted despite persistent symptoms

These are consumer complaints, not clinical adverse event reports, and they should be read as operational and service signals rather than direct evidence of clinical harm. The FTC's guidance on evaluating telehealth services is worth reviewing if you are comparing platforms.

A useful framework for evaluating any menopause telehealth platform: ask whether the service (1) screens for hormone therapy contraindications before prescribing, (2) requires a uterus check before adding progestogen, (3) follows up on symptom response at a defined interval, and (4) has a clear escalation path to in-person care. Evernow's published intake process addresses points 1 and 2 in its questionnaire design. Points 3 and 4 depend heavily on how individual clinicians respond within the platform, and that variability is where consumer complaints concentrate.

Prescribing Consistency Signals

One indirect data source is pharmacy-level prescription data aggregated by services like Definitive Healthcare and IQVIA. These are proprietary datasets, but they have been cited in industry analyses showing that direct-to-consumer menopause platforms collectively increased transdermal estradiol prescriptions in the 35-to-55 age bracket by approximately 34% between 2020 and 2023. Evernow would be a contributor to that trend, though platform-specific breakdowns are not publicly reported.

The 2023 ACOG Clinical Practice Bulletin on Menopause notes that individualized therapy, regular symptom reassessment, and the lowest effective dose for the shortest necessary duration remain the standard of care. Whether a given Evernow clinician applies that standard consistently is not verifiable from external data.

Sex-Specific Physiology: Why Menopause Telehealth Requires Specialized Clinical Judgment

Perimenopause vs. Menopause: Not the Same Clinical Problem

Perimenopause, which typically begins in the mid-to-late 40s and lasts four to eight years, involves erratic estrogen fluctuation rather than simple estrogen decline. FSH levels fluctuate widely during this phase and can be in the normal premenopausal range on the day of a blood draw, making lab-based diagnosis unreliable in isolation. A platform that relies primarily on a symptom questionnaire rather than a longitudinal clinical picture may under-recognize perimenopause or mistime the start of therapy.

Post-menopause, defined as 12 consecutive months without a menstrual period, presents a cleaner physiological target for hormone therapy. The Women's Health Initiative studied this population, and the more nuanced reanalysis by Manson et al. In JAMA (2013) clarified that women who began hormone therapy within 10 years of menopause onset had lower all-cause mortality and coronary artery disease incidence compared to those who started later.

Hormonal Acne, PCOS, and Thyroid Overlap

Women in perimenopause sometimes present with hormonal acne, PCOS-adjacent metabolic shifts, or thyroid dysfunction that can mimic or exacerbate menopause symptoms. Postpartum thyroiditis can persist into the perimenopausal years in some women. A platform focused narrowly on menopause may not screen adequately for these conditions. If you have a known thyroid disorder or PCOS history, confirm with your Evernow clinician that those conditions are part of the intake review.

Genitourinary Syndrome of Menopause (GSM)

GSM, which includes vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs, affects up to 50 to 60 percent of postmenopausal women and is significantly undertreated. Vaginal estrogen is the first-line treatment per ACOG Practice Bulletin No. 141, carries a low systemic absorption profile, and is generally safe even in women who cannot use systemic hormone therapy. Evernow does offer vaginal estrogen, which is appropriate, but whether patients are routinely screened for GSM symptoms during intake is not documented in publicly available materials.

Pregnancy, Lactation, and Contraception: A Required Clinical Note

Systemic hormone therapy as used in menopause care is contraindicated in confirmed pregnancy. This applies to estradiol in all forms (oral, transdermal patch, gel, spray) and to micronized progesterone used for endometrial protection in menopause dosing.

Perimenopause and Contraception

This is one of the most clinically important and most commonly overlooked points: perimenopause does not mean infertility. Spontaneous ovulation continues sporadically during perimenopause, and unintended pregnancies in women aged 40 to 44 account for approximately 33% of all pregnancies in that age group. If you are perimenopausal, sexually active with a male partner, and starting hormone therapy through any telehealth platform, you need a concurrent contraceptive plan.

Low-dose combined oral contraceptives (if no contraindications), progestin-only pills, hormonal IUDs, or barrier methods are all options. The 2022 ACOG Practice Bulletin on Contraception in Women Over 40 notes that hormonal IUDs also provide endometrial protection and may reduce menopause-related bleeding irregularities. Ask your Evernow clinician directly whether your contraceptive plan has been accounted for in the prescribing decision.

Lactation

Systemic estrogen in pharmacologic doses suppresses lactation and is not used in breastfeeding women. If you are postpartum and breastfeeding and experiencing early menopause-like symptoms (which can reflect postpartum estrogen decline rather than true menopause), this distinction matters clinically. Low-dose vaginal estrogen has minimal systemic absorption and is generally considered compatible with breastfeeding per LactMed, though data in lactating women specifically are limited.

Evernow's platform is not designed for postpartum or lactating women. If you are in this phase of life, a platform with a broader reproductive medicine scope or a direct conversation with an OB-GYN is more appropriate.

FDA Pregnancy Category

Under the legacy FDA pregnancy category system (still referenced in many package inserts), conjugated estrogens and estradiol carry Pregnancy Category X: evidence of fetal risk, contraindicated in pregnancy. The current FDA PLLR labeling for estradiol products states contraindication in pregnancy. The FDA labeling for estradiol patch products makes this explicit.

Who This Platform Is Right For, and Who Should Look Elsewhere

A Good Fit If You Are

• A healthy woman aged 45 to 65 in perimenopause or menopause with typical vasomotor, mood, or sleep symptoms
• Looking for access to FDA-approved hormone therapy and unwilling or unable to get a timely appointment with a local OB-GYN or menopause specialist
• Comfortable with a primarily asynchronous care model and self-directing some of your follow-up
• In a state where Evernow is licensed to operate (check at intake)
• Without major cardiovascular, thromboembolic, or active cancer history

Not a Good Fit If You Are

• Currently pregnant or trying to conceive
• Breastfeeding
• A breast cancer survivor or carrying BRCA1/2 mutations, for whom hormone therapy prescribing requires specialist-level nuance
• Experiencing unexplained uterine bleeding (requires in-person evaluation before starting hormone therapy, per ACOG)
• Living with active deep vein thrombosis, pulmonary embolism, or a known inherited thrombophilia
• Seeking care for PCOS, fertility, postpartum recovery, or thyroid disease as the primary concern
• Someone who needs rapid or predictable clinician response times for complex symptom management

Is Evernow Legit? A Straight Answer

Yes, in the regulatory sense. Evernow is not a pill mill, does not prescribe controlled substances for menopause indications, uses FDA-approved medications at standard doses, and its clinicians hold state licenses. No FDA enforcement action, no DEA action, and no state medical board disciplinary records are publicly linked to the platform as of January 2025.

The more relevant question is whether it delivers consistent, guideline-concordant care. The available evidence, drawn from consumer complaints, the absence of published outcomes data, and the structural limitations of asynchronous intake, suggests that quality is variable and depends significantly on which clinician you are assigned. That is true of nearly every telehealth platform, but it is worth naming clearly rather than assuming a branded menopause platform operates with uniformly higher standards.

The Menopause Society's 2022 position statement states directly that "the decision to use MHT should be individualized, taking into account the severity of symptoms, risk factors, and patient preferences." A platform that does not adapt that individualization to each woman's specific history is not fully meeting the guideline, regardless of which medications it prescribes.

If Evernow gets you started on appropriate hormone therapy when you have been waiting six months for a local appointment, that is a genuine clinical benefit. If it prescribes without adequate contraindication screening or fails to follow up when symptoms persist, the convenience is not worth the risk.

Comparing Evernow to the Broader Menopause Telehealth Market

Several competing platforms occupy similar space: Midi Health, Gennev (now part of Unified Women's Healthcare), Alloy, and Winona. Each has a different clinical model, pharmacy network, and pricing structure. Evernow's differentiation historically has been its symptom-tracking interface and its focus on longitudinal data collection, though no published data from that collection has appeared in peer-reviewed literature.

A 2022 review in Menopause noted that telehealth broadly improved access to menopause care for women in rural areas and for those facing cost barriers to specialist appointments, but cautioned that the absence of standardized quality metrics across platforms makes it impossible to compare clinical outcomes between services. That gap has not closed since 2022.

What to Ask Before You Subscribe

Before completing intake with Evernow or any menopause telehealth platform, get clear answers to these specific questions:

1. Will I have a live video visit with a clinician before my first prescription is written?
2. How will my clinician confirm I do not have contraindications to hormone therapy?
3. What happens if my symptoms do not improve within 8 to 12 weeks?
4. Who reviews my case if I have a complex history (cancer, cardiovascular disease, autoimmune condition)?
5. How do I reach a clinician urgently if I develop a new symptom or side effect?
6. What is your process for adjusting my dose?
7. Is my contraceptive status documented in my chart if I am perimenopausal?

If the intake process does not answer these questions before you pay, that is a signal to ask them directly or to look for a platform that does.